



Viral Epidemiology Snapshot: September 4-10, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	398	1	0.3%
Flu B	398	0	0.0%
RSV	389	33	8.5%
CoV-2 PUI	1386	179	12.9%
CoV-2 Surveillance	25	1	4.0%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	382	14	3.7%
Coronavirus 229E	382	0	0.0%
Coronavirus HKU1	382	0	0.0%
Coronavirus NL63	382	1	0.3%
Coronavirus OC43	382	0	0.0%
Metapneumovirus	382	1	0.3%
Rhinovirus/Enterovirus	382	205	53.7%
Parainfluenza 1	382	17	4.5%
Parainfluenza 2	382	1	0.3%
Parainfluenza 3	382	2	0.5%
Parainfluenza 4	382	4	1.0%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	0
No Subtype	1
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/2020) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as “no subtype”.

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line (“PUI”) shows data for all patients with symptoms or known exposures (“Patient Under Investigation”) while the purple line (“Surv.”) shows surveillance data for undergoing pre-procedure screening.

CoV-2 Positivity Rate Trends



As of 10/2021, the surveillance line shows patients who have been designated as “pre-procedure” in their testing order questionnaire, as well as participants in the employee screening program. In 9/2022 the employee screening program was ended and pre-procedure screening was at provider-discretion.

